An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines.
GV
GL Ventures
Activity from announced rounds
Activity in this selectionChina
GL Ventures is the Hillhouse-origin early-stage venture firm identified in LTZ and Clipto issuer announcements.
Recorded funding activity
LTZ develops cancer immunotherapies targeting myeloid biology. Clipto supplies tools for searching video and audio libraries, while Anew combines AI models and experiments for drug discovery. These histories remain distinct from the Hillhouse parent and named funds.
- Rounds participated in
- 5
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $440M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionAnew Labs
$290MFunding
LeadLatentVerse
LatentVerse develops foundation models that combine perception, prediction and robot action.
UndisclosedSeed
ParticipantMoSense
MoSense builds flexible tactile skin and sensing systems for robots.
UndisclosedAngel
ParticipantLitchibot
Litchibot develops physical-AI infrastructure that lets robot skills transfer across hardware.
UndisclosedSeed
ParticipantSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosed